文献发表
科学技术

Selected Scientific Publications
文献发表(部分)
  1. ​Christian Martin Kurbacher, Olympia Horn, Jutta A. Kurbacher, Susanne Herz, Ann T. Kurbacher, Ralf Hildenbrand, Reinhardt Bollmann. Outpatient intraperitoneal Catumaxomab therapy for malignant ascites related to advanced gynecologic neoplasms. The Ocologist 2015; 20:1333-1341.​​


2. Schuster FR, Stanglmaier M, Woessmann W, Winkler B, Siepermann M, Meisel R, Schlegel PG, Hess J, Lindhofer H, Borkhardt A, Buhmann R (2014). Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies. Br J Haematology. 


3. Pietzner K, Vergote I, Santoro A, Chekerov R, Marme´ F, Rosenberg P, Martinius H, Friccius-Quecke H, Sehouli J (2014). Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study. Med Oncol. 31:308. 


4. Eissler N, Ruf P, Mysliwietz J, Lindhofer H, Mocikat R (2012). Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect. 


5. Ott MG, Marmé F, Moldenhauer G, Lindhofer H, Hennig M, Spannagl R, Essing MM, Linke R, Seimetz D (2012). Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with.


6. Ströhlein M, Lordick F, Rüttinger D, Grützner K, Schemanski O, Jäger M, Lindhofer H, Hennig M, Jauch K, Peschel C, Heiss M (2011). Immunotherapy of Peritoneal Carcinomatosis with the Antibody Catumaxomab in Colon, Gastric, or Pancreatic Cancer: An Open-Label, Multi-center, Phase I/II Trial. Onkologie. 34:101-108.


7. Markus M. Heiss et al., The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int. J. Cancer 2010: 127, 2209-2221.


8. Stanglmaier M, Faltin M, Ruf P, Bodenhausen A, Schröder P, Lindhofer H (2008). Bi20 (FBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels. Int J Cancer. 123(5):1181-9.


9. Kiewe P, Hasmüller S, Kahlert S, Heinrigs M, Rack B, Marmé A, Korfel A, Jäger M, Lindhofer H, Sommer H, Thiel E, Untch M (2006). Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res. 12(10):3085-91.


10. Ruf P, Lindhofer H (2001). Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood. 98(8):2526-34.


作用机制
Triomab双特异性抗体平台
Fleximab 双特异性抗体平台
CD3双抗开发能力
文献发表